Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPT0E028 in advanced solid malignancies
NCT02350868Phase 1Completed
- Sponsor
- Taipei Medical University
- Start
- Apr 2015
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of imofinostat in solid tumor (advanced stage), sponsored by Taipei Medical University. Primary endpoints: Dose-Limiting Toxicities and Maximum Tolerated Dose, Pharmacokinetic Profile and 1 more. Started Apr 2015; status: completed.
02
Drugs
imofinostat
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02350868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02350868.